Page 26 - Wondergem

Chapter 1
24. Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32:3059- 3067
25. Okada J, Yoshikawa K, Itami M, Positron Emission Tomography Using fluorine 18-Fluorodeoxyglucose in malignant Lymphoma:A Comparison with Proliferative Activity. J nucl med 1992;33:325-329
26. Schöder H, Noy A, Gönen M et al. Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643-4651.
27. Ngeow JYY, Quek RHH, Ng DCE et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol 2009;20:1543- 1547
28. Bodet-Millin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/ CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 2008;93: 471-472.
29. Noy A, Schöder H, Gönen M, et al. The majority of transformed lymphomas have high standardized uptake values on positron emission tomography scanning similar to diffuse large B-cell lymphoma. Ann Oncol. 2009;20:508-512.
30. Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med. 1998;4:1334-1336.
31. Toyohara J, Waki A, Takamatsu S et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29: 281-287.
32. Been LB, Suurmeijer AJH, Cobben DCP, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004;31:1659-1672
33. Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F]3’-deoxy-3’-Fluorothymidine-PET in NHL patients: whole body biodistribution and imaging of lymphoma manifestations- a pilot study. Cancer Biother Radiopharm. 2004;19:436-442.
34. Buck AK, Bommer M, Stilgenbauer S et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055-11061.
35. Ban-Hoeffen M, Vanderplas A, Crosby-Thompson AL et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013;163(4):487-495
36. Tan D, Rosenberg SA, Levy R, et al. Survival in follicular lymphoma: the Stanford experience 1960-2003. Blood 2007;110: abstract 3428
37. Lerch K, Meyer AH, Stroux A et al. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed diffuse large B cell lymphoma: a retrospective multicenter analysis. Ann Hematol 2015 feb epub.
38. Villa D, Crump M, Panzarella T et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol. 2013;31(9):1164-1171
39. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011:377(9759):42-51
40. Nastoupil LJ, Sinha R, Byrtek M et al. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 2014;120(12):1830-1837
41. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow up. M. Dreyling, M. Ghielmini, R. Marcus et al. on behalf of the ESMO guidelines working group. Ann Oncol 2014;25:1176-1182
42. Churpek JE, Pro B, van Besien K, et al. A Phase 2 Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas. Cancer 2013;119: 1683-1689
43. Czuczman MS, Vose JM, Witzig TE et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol. 2011:154(4):477-481
44. El Helw LM, Lorigan PC, Robinson MH et al. VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin’s lymphoma. Int J Oncol 2000;16:777-782
24